Toronto, ON; March 5, 2025 –Proteocyte AI—an innovative company that develops and commercializes individualized tests to predict risk of developing cancer, has recently learned that two unique abstracts involving their oral cancer predictive test, Straticyte™, have been accepted to upcoming industry conferences this spring.
The first titled “Estimated Downstream Cost Savings Associated With a Novel Prognostic Biomarker Assay – Straticyte – Based on the Distribution of Lesions Identified at Localized vs Regional and Distant Stage” has been accepted to The American Academy of Oral & Maxillofacial Pathology (AAOMP) Annual Meeting, April 4-7 in Pittsburgh. This study estimated the proportions of localized vs regional and distant cancers identified using Straticyte and oral epithelial dysplasia grading (OEDG) in the US population and compared the direct care costs associated with managing patients across different cancer stages. The findings will be presented as a poster.
The second titled “Evaluating StraticyteTM In Community-Based, Oral Surgery Practices For Malignant Transformation Potential in Oral Epithelial Dysplasia” was accepted by the The American Academy of Oral Medicine (AAOM) for their Global Transformations in Oral Medicine Conference, May 14-17 in Las Vegas. A quantitative biomarker-based risk assay (StraticyteTM; Proteocyte AI) was previously shown to enhance the shortcomings of oral epithelial dysplasia (OED) grading. In this study, a prospective cohort consisting of biopsied OPMD in community-based oral surgery practices was used to assess Straticyte’s clinical utility. The findings will be presented as a poster.
“We want to continue building our momentum and awareness of what Straticyte is capable of, and how it can be utilized to help not only the patients and clinicians dealing with the uncertainties surrounding the management of oral epithelial dysplasia, but also the impact this technology could have on the healthcare system.” States Jason Hwang, Principal Scientist and lab manager at Proteocyte AI.
– 30 –
About Proteocyte
Proteocyte is a personalized medical diagnostics company located at the MaRS Centre, in Toronto, Ontario. Proteocyte’s product helps tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, Straticyte™, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.
For more information please contact:
Todd Conrad
Sales & Marketing Advisor
416-779-4806
[email protected]